HeartBeat Podcast

著者： Mohammed Al-Qadami
無料で聴く

  • サマリー

  • Welcome to the HeartBeat Podcast, your trusted source for the latest discoveries and advancements in cardiology. This podcast leverages advanced AI tools to analyze, summarize, and transform cutting-edge medical research into high-quality podcast episodes. While artificial intelligence plays a key role in producing and presenting these episodes, the content is carefully curated and crafted to ensure accuracy, reliability, and clarity. Whether you're a doctor, a student, or someone passionate about cardiology, this podcast offers insightful and inspiring episodes that combine the power of tec
    Mohammed Al-Qadami
    続きを読む 一部表示

あらすじ・解説

Welcome to the HeartBeat Podcast, your trusted source for the latest discoveries and advancements in cardiology. This podcast leverages advanced AI tools to analyze, summarize, and transform cutting-edge medical research into high-quality podcast episodes. While artificial intelligence plays a key role in producing and presenting these episodes, the content is carefully curated and crafted to ensure accuracy, reliability, and clarity. Whether you're a doctor, a student, or someone passionate about cardiology, this podcast offers insightful and inspiring episodes that combine the power of tec
Mohammed Al-Qadami
衛生・健康的な生活 身体的病い・疾患
続きを読む 一部表示
エピソード
  • Impella CP: Can Microaxial Flow Pumps Redefine Cardiogenic Shock Treatment? Insights from the DanGer Shock Study

    Impella CP: Can Microaxial Flow Pumps Redefine Cardiogenic Shock Treatment? Insights from the DanGer Shock Study
    2025/02/16

    In this episode, we explore the DanGer Shock study, which investigated the efficacy of the microaxial flow pump Impella CP in reducing mortality and improving clinical outcomes in patients with STEMI-related cardiogenic shock. We delve into the study's design, statistical findings, clinical recommendations, and the future of mechanical circulatory support in cardiology, highlighting both the benefits and risks of this advanced technology as published in the NEJM.


    Links to the Podcast

    • Apple Podcast:⁠⁠⁠Listen on Apple Podcast⁠⁠⁠
    • Spotify:⁠⁠⁠Listen on Spotify⁠⁠⁠
    • Amazon Music:⁠⁠⁠Listen on Amazon Music⁠⁠⁠
    • YouTube:⁠⁠⁠Watch on YouTube⁠⁠⁠


    📚 Source:
    Study Title: Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock (DanGer Shock Trial)
    Publication Date: April 2024
    Journal: NEJM
    DOI:10.1056/NEJMoa2312572


    #MedicalPodcast #Cardiology #CardiogenicShock #ImpellaCP #DanGerShockStudy #MyocardialInfarction #MicroaxialFlowPump #CirculatorySupport #NEJM #HeartFailure #ClinicalResearch #HeartDevices #Podcast


    続きを読む 一部表示
    11 分
  • Breathing Easier: How Aficamten is Giving New Hope to HCM Patients

    Breathing Easier: How Aficamten is Giving New Hope to HCM Patients
    2025/02/09

    In this episode, we dive into the lives of patients with hypertrophic cardiomyopathy (HCM) and how Aficamten is offering them hope for a better future. From breathing easier to avoiding surgery, we’ll uncover the real impact of this new treatment backed by the SEQUOIA-HCM trial. If you care about heart health or know someone living with HCM, this one’s for you.


    Links to the Podcast

    • Apple Podcast:⁠⁠Listen on Apple Podcast⁠⁠
    • Spotify:⁠⁠Listen on Spotify⁠⁠
    • Amazon Music:⁠⁠Listen on Amazon Music⁠⁠
    • YouTube:⁠⁠Watch on YouTube⁠⁠


    📝Source:

    Study Title: Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM Trial)

    Publication Date: May 13, 2024

    NEJM.org - SEQUOIA-HCM Trial

    🔗Full Study Details:NEJM - SEQUOIA-HCM Study
    🔗ClinicalTrials.gov:SEQUOIA-HCM NCT05186818


    #BreathingEasier #HeartHealth #Aficamten #NewHope #SEQUOIAHCM #CardiologyTalk #Podcast #RealImpact #MedicalBreakthroughs #BetterLiving
    続きを読む 一部表示
    16 分
  • Empagliflozin’s Impact: Long-Term Cardiorenal Protection for CKD Patients

    Empagliflozin’s Impact: Long-Term Cardiorenal Protection for CKD Patients
    2025/02/02

    In this episode, we explore the groundbreaking results of the EMPA-KIDNEY trial, a large-scale clinical study that highlights the long-term benefits of Empagliflozin (SGLT2 inhibitor) in patients with chronic kidney disease (CKD). We dive into how the treatment slowed disease progression, reduced cardiovascular deaths, and provided lasting benefits even after the therapy ended. Join us as we break down the study’s key findings, discuss their real-world implications, and uncover what makes this treatment a game-changer for CKD management.

    🔗 Full Study Details: NEJM - EMPA-KIDNEY Study
    🔗 ClinicalTrials.gov: EMPA-KIDNEY NCT03594110


    Links to the Podcast

    • Apple Podcast: ⁠Listen on Apple Podcast⁠
    • Spotify: ⁠Listen on Spotify⁠
    • Amazon Music: ⁠Listen on Amazon Music⁠
    • YouTube: ⁠Watch on YouTube⁠


    #Podcast #Empagliflozin #ChronicKidneyDisease #CKDManagement #EMPA_KIDNEY_Study #SGLT2Inhibitors #RenalHealth #CardioRenalProtection #ClinicalResearch #MedicalBreakthroughs #LongTermBenefits
    続きを読む 一部表示
    16 分
activate_buybox_copy_target_t1

HeartBeat Podcastに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。